Description

The Value of BCG and TNF  in Autoimmunity provides an overview of current research and thinking related to tumor necrosis factor (TNF) induction and the use of the bacillus Calmette-Guérin (BCG) vaccine as potential treatment approaches to diverse forms of autoimmunity. BCG, commonly known as an anti-tuberculosis vaccine, is being explored in worldwide clinical trials as an approach to the treatment of certain forms of autoimmunity. The scope of research behind this therapeutic approach spans from the basic science of TNF signaling to research in diverse autoimmune disciplines, such as type 1 diabetes and multiple sclerosis.

Overall, the book focuses on the lessons that can be learned from the researchers' individual experiences and data, and provides a rationale for bringing the inexpensive, generic BCG vaccine to the forefront of clinical trials in different forms of autoimmunity.

Key Features

  • Editor awarded 2005: Oprah Achievement Award," Top Health Breakthrough by a Female Scientist"
  • Brings into one resource the international scientific literature on a unique way to treat autoimmunity
  • Provides a different perspective on treatment approaches for certain autoimmune conditions
  • Discusses TNF induction, rather than anti-TNF, as a therapeutic pathway for autoimmunity treatment

Readership

This book is intended for clinical researchers and scientists working in the fields of autoimmunity and/or immunology.

Table of Contents

  • List of Contributors
  • Introduction
  • Chapter 1. Mycobacteria, Immunoregulation, and Autoimmunity
    • 1.1 Introduction
    • 1.2 Increases in Inflammatory Disorders
    • 1.3 Progressive Loss of Microbial Inputs
    • 1.4 Old Friends and Immunoregulation
    • 1.5 Humans and Mycobacteria
    • 1.6 Mycobacteria, TNF, and T1D
    • 1.7 Conclusions
    • References
  • Chapter 2. Prevention of Type 1 Diabetes and Its Recurrence by Immunotherapy with Mycobacterial Adjuvants
    • 2.1 Introduction
    • 2.2 Mechanism of Action of AIT
    • 2.3 Regeneration of Islet Cells by AIT
    • 2.4 Microbiota and AIT
    • 2.5 Conclusions
    • Acknowledgements
    • References
  • Chapter 3. Proteasome Defects and Cytokine Signaling in Sjögren’s Syndrome
    • 3.1 Introduction
    • 3.2 Involvement of the Proteasome System in Regulation of Foreign and Self-Directed Inflammation and Immunity
    • 3.3 The Proteasome System in Sjögren’s Syndrome
    • 3.4 Cytokine Signaling and Treatment Approaches in Sjögren’s Syndrome
    • References
  • Chapter 4. The Protective Effect of the BCG Vaccine on the Development of Type 1 Diabetes in Humans
    • 4.1 Introduction
    • 4.2 Methods
    • 4.3 Results
    • 4.4 Discussion
    • References
  • Chapter 5. Effects of the Bacillus Calmette-Guérin (BCG) Vaccine in the Demyelinating Disease of the Central Nervous System
    • 5.1 Introduction
    • 5.2 The BCG Vaccine in Patients with Relapsing-Remitting MS
    • 5.3 BCG in People with Clinically Isolated Syndromes
    • 5.4 The Future
    • References
  • Chapter 6. TNF, BCG, and the Proteasome in Autoimmunity: An Overview of the Pathways & Results of a Phase I Study in Type 1 Diabetes
    • 6.1 Introduction
    • 6.2 Abnormal Class I Structures Genera

Details

No. of pages:
164
Language:
English
Copyright:
© 2014
Published:
Imprint:
Academic Press
Electronic ISBN:
9780128004616
Print ISBN:
9780127999647

About the editor

Denise Faustman

Denise L. Faustman, MD, PhD, is Director of the Immunobiology Laboratory at the Massachusetts General Hospital (MGH) and an Associate Professor of Medicine at Harvard Medical School. She has worked in the field of autoimmunity for nearly two decades. In 2001, the Faustman Lab reversed type 1 diabetes in mice with end-stage disease, a project that is now in human clinical trials. Dr. Faustman’s current research is focused on uncovering new treatments for type 1 diabetes, as well as searching for therapies for other autoimmune diseases, including Crohn's disease, lupus, scleroderma, rheumatoid arthritis, Sjögren's syndrome, and multiple sclerosis. Dr. Faustman’s earlier research achievements include key discoveries regarding the role of MHC Class I antigen presentation in immunity and introducing the concept of modifying antigens on donor tissues to prevent their rejection. After completing her internship, residency, and fellowships in Internal Medicine and Endocrinology at the MGH, Dr. Faustman became an independent investigator at the MGH and Harvard Medical School in 1987. She is a member of the American Association for the Advancement of Science (AAAS) and serves as a frequent member of the Institute of Medicine in Washington, DC. Dr. Faustman's honors in recent years include: ~2003: National Institutes of Health and the National Library of Medicine, "Changing the Face of Medicine" award - one of 300 American physicians honored for achievement in medicine, past and present ~2005: Oprah Achievement Award," Top Health Breakthrough by a Female Scientist" ~2006: The American Medical Women's Association and Wyeth Pharmaceutical Company “Women in Science Award,” given to a female physician who has made exceptional contributions to medical science through basic science publications and leadership in the field ~2011: The Goldman Philanthropic Partnerships/Partnership for Cures “2011 George and Judith Goldman Angel Award” for research to find an effective treatm